id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-P-0326-0004,FDA,FDA-2010-P-0326,"FDA/CDER to JRRapoza Associates, Inc. - Response Letter",Other,LET-Letter,2011-01-03T05:00:00Z,2011,1,2011-01-03T05:00:00Z,,2013-08-11T01:39:04Z,,0,0,0900006480bc4368
FDA-2010-P-0326-0003,FDA,FDA-2010-P-0326,"Determination that Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness: TRANDATE (Labetalol Hydrochloride) Tablets, 300 Milligrams and 400 Milligrams",Notice,N-Notice,2010-12-28T05:00:00Z,2010,12,2010-12-28T05:00:00Z,,2010-12-28T16:37:57Z,2010-32507,0,0,0900006480bc11ac
FDA-2010-P-0326-0001,FDA,FDA-2010-P-0326,"J R Rapoza Associates, Inc. - Citizen Petition",Other,CP-Citizen Petition,2010-06-30T04:00:00Z,2010,6,2010-06-30T04:00:00Z,,2013-07-27T23:22:47Z,,0,0,0900006480b0800d
FDA-2010-P-0326-0002,FDA,FDA-2010-P-0326,"Acknowledgement Letter to J R Rapoza Associates, Inc.",Other,ACK-Acknowledgement Letter,2010-06-30T04:00:00Z,2010,6,2010-06-30T04:00:00Z,,2013-07-27T23:22:50Z,,0,0,0900006480b0819d